ライフサイエンスコーパス: bioprostheses

1 agement of structural degeneration of aortic bioprostheses.

2 rtant drawback of surgical and transcatheter bioprostheses.

3 both transcatheter and surgical aortic valve bioprostheses.

4 a viable option for treatment of failing TV bioprostheses.

5 n degenerate in a manner similar to surgical bioprostheses.

6 -TAVR with Edwards SAPIEN balloon-expandable bioprostheses.

7 types, including transcatheter and surgical bioprostheses.

8 rmacologic treatments and developing durable bioprostheses.

9 valve deterioration (SVD) is a major flaw of bioprostheses.

10 agulation in patients receiving aortic valve bioprostheses.

11 structural deterioration and reoperation of bioprostheses.

12 eses are hemodynamically superior to stented bioprostheses.

13 hanical valves and the limited durability of bioprostheses.

14 are superior with newer compared with older bioprostheses.

15 mall, Severely Dysfunctional Surgical Aortic Bioprostheses.

16 r, self-expanding transcatheter, or surgical bioprostheses.

17 All had tricuspid valve replacement (159 bioprostheses, 36 mechanical), and 157 underwent a pulmo

18 The lack of durable bioprostheses and pharmacologic therapies remain central

19 practice is limited to patients with failing bioprostheses and rings or mitral valve disease associat

20 Survival was lower among patients with small bioprostheses and those with predominant surgical valve

21 Both stented and stentless bioprostheses are associated with excellent clinical and

22 It is presumed that stentless aortic bioprostheses are hemodynamically superior to stented bi

23 hetic heart valves, though more durable than bioprostheses, are more thrombogenic and require lifelon

24 ts >/=65 years of age receiving aortic valve bioprostheses at 797 hospitals within the Society of Tho

25 anding TAVR in patients with failed surgical bioprostheses at extreme risk for surgery was associated

26 symptomatic degeneration of surgical aortic bioprostheses at high risk (>/=50% major morbidity or mo

27 symptomatic degeneration of surgical aortic bioprostheses at high risk (>=50% major morbidity or mor

28 series who required reoperation had received bioprostheses at the first operation.

29 late valve degeneration (VD) associated with bioprostheses (BPs).

30 egenerated surgical aortic valve replacement bioprostheses, but their clinical impact is uncertain.

31 long-term durability of current pericardial bioprostheses compares with the traditional porcine biop

32 In an ovine model, tubular SIS-ECM TV bioprostheses demonstrate "growth" and a cell-matrix str

33 vidence of accelerated deterioration of such bioprostheses during pregnancy.

34 (Registry of Aortic Valve Bioprostheses Established by Catheter [FRANCE TAVI]; NCT

35 ationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 p

36 rnative for patients with degenerated mitral bioprostheses, failed surgical repairs with annuloplasty

37 At present, bioprostheses for the diseased aortic valve include sten

38 omes of the ACURATE neo and CoreValve Evolut bioprostheses for transcatheter aortic valve replacement

39 Few randomized trials have compared bioprostheses for transcatheter aortic valve replacement

40 dysfunctional surgical tricuspid valve (TV) bioprostheses has been described in small reports.

41 Patients receiving aortic valve bioprostheses have an elevated early risk of thromboembo

42 ves, stentless bioprosthesis, and sutureless bioprostheses have been proposed to improve valve hemody

43 ghty-five percent of SAVR patients receiving bioprostheses have low surgical risk.

44 rmed with homografts in 98.6% (n = 1189) and bioprostheses in 1.4% (n = 17).

45 ess the safety of AVR with other pericardial bioprostheses in children and the youngest adults.

46 c valve replacement with currently available bioprostheses in patients with a mean age <55 years, pub

47 s will increasingly present with degenerated bioprostheses in the next few years.

48 Conclusions Aortic valve replacement with bioprostheses in young adults is associated with high st

49 nt (AVR) with current-generation pericardial bioprostheses in young patients is limited.

50 The use of bioprostheses in young women anticipating future pregnan

51 However, the durability of bioprostheses is still a matter of concern, and little i

52 he presence of thrombi, and in patients with bioprostheses, is discussed.

53 ients with ventricular impairment, stentless bioprostheses may allow for greater improvement in left

54 ung women, transseptal TMVI to treat failing bioprostheses may result in good short-term outcomes tha

55 ACURATE neo (n=398) or the CoreValve Evolut bioprostheses (n=398).

56 Structural deterioration of bioprostheses occurred in 64 patients (2.4%).

57 With new bioprostheses on the horizon, there is renewed interest

58 comes in high-risk patients with degenerated bioprostheses or failed annuloplasty rings, but mitral V

59 ts after aortic valve replacement (AVR) with bioprostheses or mechanical prostheses.

60 the primary biomaterial used in heart valve bioprostheses, recipient graft-specific immune responses

61 araldehyde cross-linked porcine aortic valve bioprostheses represents a highly efficacious and mechan

62 d 5.2% for transcatheter and surgical aortic bioprostheses, respectively (hazard ratio, 1.2; 95% CI,

63 ant risk of reoperation following the use of bioprostheses suggests that mechanical valves may be und

64 d (18)F-NaF uptake around the outside of the bioprostheses that showed a modest correlation with the

65 Among 397 consecutive cases of explanted bioprostheses, there were 46 cases of BPVT (11.6%; aorti

66 In patients with small failed aortic bioprostheses, ViV-TAVR with an SEV was associated with

67 a considerable increase in the use of aortic bioprostheses (vs. mechanical prostheses) for treating a

68 Structural deterioration of aortic bioprostheses was rare.

69 Bioprostheses were associated with a higher long-term ri

70 Stentless aortic bioprostheses were designed to provide enhanced hemodyna

71 tomographic imaging abnormalities of aortic bioprostheses were frequent but dynamic in the first yea

72 Bioprostheses were used in 145 (69%) and mechanical pros

73 lve replacement, and no trials have compared bioprostheses with supra-annular design.